234 related articles for article (PubMed ID: 23996800)
21. AS602801 sensitizes glioma cells to temozolomide and vincristine by blocking gap junction communication between glioma cells and astrocytes.
Zhang S; Gong Y; Wang H; Li Z; Huang Y; Fu X; Xiang P; Fan T
J Cell Mol Med; 2021 Apr; 25(8):4062-4072. PubMed ID: 33609076
[TBL] [Abstract][Full Text] [Related]
22. Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide.
Chai KM; Wang CY; Liaw HJ; Fang KM; Yang CS; Tzeng SF
Oncotarget; 2014 Nov; 5(21):10901-15. PubMed ID: 25337721
[TBL] [Abstract][Full Text] [Related]
23. Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide.
Schmid RS; Simon JM; Vitucci M; McNeill RS; Bash RE; Werneke AM; Huey L; White KK; Ewend MG; Wu J; Miller CR
Neuro Oncol; 2016 Jul; 18(7):962-73. PubMed ID: 26826202
[TBL] [Abstract][Full Text] [Related]
24. New advances of microRNAs in glioma stem cells, with special emphasis on aberrant methylation of microRNAs.
Zhao B; Bian EB; Li J; Li J
J Cell Physiol; 2014 Sep; 229(9):1141-7. PubMed ID: 24374932
[TBL] [Abstract][Full Text] [Related]
25. Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine for the treatment of malignant glioma.
Wang Y; Huang N; Li H; Liu S; Chen X; Yu S; Wu N; Bian XW; Shen HY; Li C; Xiao L
Oncotarget; 2017 Jun; 8(23):37511-37524. PubMed ID: 28415586
[TBL] [Abstract][Full Text] [Related]
26. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways.
Sun S; Lee D; Ho AS; Pu JK; Zhang XQ; Lee NP; Day PJ; Lui WM; Fung CF; Leung GK
Neuro Oncol; 2013 May; 15(5):562-77. PubMed ID: 23444257
[TBL] [Abstract][Full Text] [Related]
28. Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells.
Qiu ZK; Shen D; Chen YS; Yang QY; Guo CC; Feng BH; Chen ZP
Chin J Cancer; 2014 Feb; 33(2):115-22. PubMed ID: 23958055
[TBL] [Abstract][Full Text] [Related]
29. Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells.
Datta S; Sears T; Cortopassi G; Woolard K; Angelastro JM
Biomed Pharmacother; 2021 Jan; 133():111058. PubMed ID: 33378970
[TBL] [Abstract][Full Text] [Related]
30. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
Yu Z; Zhao G; Xie G; Zhao L; Chen Y; Yu H; Zhang Z; Li C; Li Y
Oncotarget; 2015 Oct; 6(32):32930-43. PubMed ID: 26431379
[TBL] [Abstract][Full Text] [Related]
31. Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide.
Li H; Yuan X; Yan D; Li D; Guan F; Dong Y; Wang H; Liu X; Yang B
Cell Physiol Biochem; 2017; 42(3):1192-1201. PubMed ID: 28668966
[TBL] [Abstract][Full Text] [Related]
32. Repurposing phenformin for the targeting of glioma stem cells and the treatment of glioblastoma.
Jiang W; Finniss S; Cazacu S; Xiang C; Brodie Z; Mikkelsen T; Poisson L; Shackelford DB; Brodie C
Oncotarget; 2016 Aug; 7(35):56456-56470. PubMed ID: 27486821
[TBL] [Abstract][Full Text] [Related]
33. MDM2 Degrades Deacetylated Nucleolin Through Ubiquitination to Promote Glioma Stem-Like Cell Enrichment for Chemotherapeutic Resistance.
Ko CY; Lin CH; Chuang JY; Chang WC; Hsu TI
Mol Neurobiol; 2018 Apr; 55(4):3211-3223. PubMed ID: 28478507
[TBL] [Abstract][Full Text] [Related]
34. Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein.
Zhitao J; Long L; Jia L; Yunchao B; Anhua W
Tumour Biol; 2015 Dec; 36(12):9621-30. PubMed ID: 26142735
[TBL] [Abstract][Full Text] [Related]
35. Reversing glioma malignancy: a new look at the role of antidepressant drugs as adjuvant therapy for glioblastoma multiforme.
Bielecka-Wajdman AM; Lesiak M; Ludyga T; Sieroń A; Obuchowicz E
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1249-1256. PubMed ID: 28500556
[TBL] [Abstract][Full Text] [Related]
36. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
[TBL] [Abstract][Full Text] [Related]
37. Temozolomide-induced modification of the CXC chemokine network in experimental gliomas.
Bruyère C; Mijatovic T; Lonez C; Spiegl-Kreinecker S; Berger W; Kast RE; Ruysschaert JM; Kiss R; Lefranc F
Int J Oncol; 2011 May; 38(5):1453-64. PubMed ID: 21399866
[TBL] [Abstract][Full Text] [Related]
38. PLK1 inhibitor facilitates the suppressing effect of temozolomide on human brain glioma stem cells.
Liu N; Hu G; Wang H; Li Z; Guo Z
J Cell Mol Med; 2018 Nov; 22(11):5300-5310. PubMed ID: 30133120
[TBL] [Abstract][Full Text] [Related]
39. DNMT1 mediates chemosensitivity by reducing methylation of miRNA-20a promoter in glioma cells.
Zhou D; Wan Y; Xie D; Wang Y; Wei J; Yan Q; Lu P; Mo L; Xie J; Yang S; Qi X
Exp Mol Med; 2015 Sep; 47(9):e182. PubMed ID: 26337869
[TBL] [Abstract][Full Text] [Related]
40. Combination of temozolomide and Taxol exerts a synergistic inhibitory effect on Taxol‑resistant glioma cells via inhibition of glucose metabolism.
Guan DG; Chen HM; Liao SF; Zhao TZ
Mol Med Rep; 2015 Nov; 12(5):7705-11. PubMed ID: 26459853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]